Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Kontafarma China Holdings Ltd ( (HK:1312) ) has provided an announcement.
Kontafarma China Holdings Ltd, through its subsidiary Tongfang Pharmaceutical, has entered into a construction contract with Beijing Qingkong for the development of a new R&D complex in Beijing, valued at approximately RMB33.67 million. This transaction is considered both discloseable and connected, requiring independent shareholder approval due to its association with the company’s controlling shareholder, Shenzhen Waranty. The project is expected to strengthen Kontafarma’s research capabilities, potentially impacting its market position positively.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd operates in the pharmaceutical industry, primarily focusing on research and development. The company is involved in the construction of R&D complexes to enhance its capabilities in the pharmaceutical sector.
Average Trading Volume: 1,142,666
Technical Sentiment Signal: Sell
Current Market Cap: HK$172.9M
See more insights into 1312 stock on TipRanks’ Stock Analysis page.